Merck KGaA completes MBO of UK clinical research unit
Merck Sante SAS, the French pharmaceutical subsidiary of German company Merck KgaA, has sold its entire share capital in Simbec Research to a buy-out group formed by Simbec's current senior management team.
Merck Sante SAS, the French pharmaceutical subsidiary of German company Merck KgaA, has sold its entire share capital in Simbec Research to a buy-out group formed by Simbec's current senior management team.
Simbec Research is a clinical research organisation based in Merthyr Tydfil, South Wales, UK. The company, with a workforce of approximately 80 people, specialises in early clinical r&d services for customers outside the Merck Group.
'With this step, we create an independent, self-standing clinical research organisation that will continue to focus on excellent services for our customers in the pharmaceutical industry,' said Brian Hallisey, managing director of Simbec Research.
The buy-out, led by Hallisey, finance director Howard Jenkins and scientific director Dr Trevor Tanner, was completed on 31 July, 2003. Simbec Research was acquired by Merck as part of the French pharmaceutical company Lipha in 1991.